Page 105 - Recognizing axial spondyloarthritis - Janneke de Winter

Conclusions
In conclusion, the absence of HLA-C*07 is strongly associated with susceptibility to axSpA, including both AS and non-radiographic axSpA. Future research needs to 1) study HLA-C*07 prevalence in other, larger axSpA populations, thereby controlling for a possible LD between HLA-B*27 and HLA-C*07, 2) study the role of HLA-C*07 in axSpA pathogenesis, focusing on new bone formation and 3) examine HLA-C*07 as a biological marker for axSpA diagnosis, prognosis, or classification.
Acknowledgements: We acknowledge Prof. Martin Rudwaleit and Prof. Joachim Sieper for their role in establishing GESPIC. We thank Junior Lardy, PhD for his help with the HLA-typing. GESPIC has been financially supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung – BMBF). As funding by BMBF was reduced according to schedule in 2005 and stopped in 2007, complementary financial support has been obtained also from Abbott / Abbvie, Amgen, Centocor, Schering-Plough, and Wyeth. Since 2010 GESPIC is supported by Abbvie. Additional support has being obtained also from ANCYLOSS (grant number FKZ 01EC1002D), ArthroMark (grants numbers FKZ 01EC1009A and FKZ 01EC1401A) and METARTHROS (grant number FKZ 01EC1407A) projects funded by BMBF. DB is supported by a VICI grant from the Netherlands Scientific Organization (NWO), a Consolidator grant from the European Research Council (ERC) and a grant from the Dutch Arthritis Foundation (Reumafonds).
HLA-C*07 IN AXIAL SPA
103
SIX